Greener HPLC Method Promises Safer Quality Control for Antidepressant Sertraline

Sertraline hydrochloride, one of the most widely prescribed antidepressants in the world, has long relied on laboratory testing methods that are slow, solvent-hungry, and sometimes unable to fully separate the drug from its chemical impurities. A team of pharmaceutical scientists working across laboratories in the United States has now unveiled a redesigned analytical method that promises to change that. Writing in the journal Discover Chemistry, the researchers describe a stability-indicating reversed-phase high-performance liquid chromatography method, built with Analytical Quality by Design principles and assessed for environmental sustainability, that can simultaneously quantify sertraline and six related impurities in finished capsule formulations with unprecedented clarity and robustness.

The stakes behind this seemingly technical achievement are considerable. Impurity control sits at the heart of pharmaceutical safety: trace contaminants that slip past inadequate analytical methods can compromise therapeutic efficacy or, in the worst cases, pose direct risks to patients. Sertraline, chemically known as (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine hydrochloride, is a selective serotonin reuptake inhibitor that works by blocking serotonin reabsorption at presynaptic nerve terminals, enhancing neurotransmission in the central nervous system. During its synthetic preparation, structurally related impurities can arise, and regulators such as the International Council for Harmonisation require comprehensive impurity profiling and stability evaluation to guarantee product quality throughout a medicine’s shelf life.

Existing methods for sertraline impurity testing, the authors note, have been limited by empirical optimization, long run times, high solvent consumption, inadequate impurity resolution, and limited robustness. The drug substance is official in both the United States Pharmacopoeia and the European Pharmacopoeia, yet the pharmacopeial approaches rely on gas chromatography for specified organic impurities. The research team set out to close this gap by combining two modern paradigms: Analytical Quality by Design, often abbreviated AQbD, which applies systematic, risk-based experimentation to analytical method development, and Green Analytical Chemistry, which seeks to minimize the environmental footprint of laboratory work.

The journey to the final method was one of iterative refinement. Early attempts using an isocratic elution of potassium dihydrogen phosphate and acetonitrile on a conventional column failed entirely, with all impurity peaks eluting at the same retention time. Switching to methanol improved matters only marginally, producing broad peaks, while gradient programs and a phenyl column achieved separation but with unsatisfactory peak shapes caused by isomeric compounds. The breakthrough came with a pentafluorophenyl-modified C18 column, the ACE 5 C18 PFP, whose special surface chemistry offers multiple retention mechanisms, including hydrophobic, pi-pi, dipole-dipole, and hydrogen-bonding interactions, providing enhanced selectivity for structurally similar aromatic impurities that defeat ordinary C18 columns.

The optimized method uses a gradient of two mobile phases built around a 20 millimolar ammonium phosphate buffer adjusted to pH 4.2, mixed with methanol and acetonitrile in carefully tuned ratios. Mobile phase A combines buffer, methanol, and acetonitrile at 80:10:10, while mobile phase B blends methanol, acetonitrile, and buffer at 50:20:30. Separation proceeds on the 250 by 4.6 millimeter column at 40 degrees Celsius with a flow rate of 1.0 milliliter per minute and ultraviolet detection at 254 nanometers. Under these conditions, the six impurities elute at distinct retention times ranging from roughly 4 minutes for impurity-E to nearly 42 minutes for impurity-F, with sertraline itself appearing at about 22 minutes, all fully resolved from blank and placebo signals.

Crucially, the team did not simply tune parameters by trial and error. They identified column temperature and flow rate as critical method parameters and subjected them to a three-level, two-factor Design of Experiments, running thirteen HPLC experiments and modeling the results with response surface methodology. Statistical analysis confirmed that neither variable significantly affected the relative retention times of the key impurities, establishing a design space within which the method remains reliable. This systematic approach, validated against ICH Q2(R2) guidelines, demonstrated excellent linearity across concentration ranges of approximately 0.2 to 5.0 micrograms per milliliter with correlation coefficients exceeding 0.999, precision with relative standard deviations below 2 percent, and recoveries between 99.0 and 103.0 percent.

The method’s stability-indicating power was tested through forced degradation studies that subjected sertraline capsules to acidic, alkaline, oxidative, hydrolytic, thermal, photolytic, and humidity stress. Samples were treated with hydrochloric acid or sodium hydroxide at 60 degrees Celsius, exposed to 10 percent hydrogen peroxide, irradiated with more than 1.2 million lux hours of light per ICH Q1B, heated to 100 degrees Celsius for three days, or held at 90 percent relative humidity. Sertraline proved remarkably stable, with only limited degradation observed under all conditions. Where degradation products did form, they were cleanly resolved from the analyte peak, and photodiode array peak purity analysis confirmed the sertraline peak remained spectrally homogeneous, with satisfactory mass balance values throughout.

Perhaps the most distinctive feature of the study is its environmental assessment. Using two established greenness metrics, the AGREE analytical tool and the Green Analytical Procedure Index, the researchers scored their method at 0.79 and 84 respectively, indicating high environmental compatibility. The method earns green ratings for low sample consumption, minimal preparation steps, automation, avoidance of derivatization, waste control, and energy efficiency. In an era when laboratories worldwide are under pressure to reduce their reliance on hazardous solvents, the deliberate balancing of acetonitrile consumption against chromatographic performance represents a meaningful step toward sustainable pharmaceutical quality control.

The researchers report that sample and mobile phase solutions remained stable for up to 72 hours at room temperature, further supporting the method’s suitability for routine work. With its combination of complete impurity resolution, regulatory-compliant validation, statistically proven robustness, and favorable environmental profile, the AQbD-driven method offers pharmaceutical manufacturers a practical tool for both routine quality control and formal stability testing of sertraline capsules. As analytical laboratories increasingly embrace Quality by Design thinking and green chemistry principles, this study offers a template for how the two movements can converge, transforming the humble chromatogram into evidence of both patient safety and environmental responsibility.

Subject of Research: Development of a stability-indicating RP-HPLC method with Analytical Quality by Design and greenness assessment for quantifying impurities in sertraline hydrochloride dosage forms

Article Title: A stability-indicating RP-HPLC method for quantification of impurities in sertraline hydrochloride finished dosage forms using quality by design with environmental assessment

Article References: Bypaneni, V., Pinnenti, M. K., Temmanaboyina, G., Sambu, P., & Nagisetti, B. M. K. (2026). A stability-indicating RP-HPLC method for quantification of impurities in sertraline hydrochloride finished dosage forms using quality by design with environmental assessment. Discover Chemistry, 3(1), Article 569. https://doi.org/10.1007/s44371-026-01010-y

Image Credits: AI Generated

DOI: 10.1007/s44371-026-01010-y

Keywords: sertraline hydrochloride, RP-HPLC, Analytical Quality by Design, impurity profiling, forced degradation, green analytical chemistry, AGREE, GAPI, pharmaceutical quality control, stability-indicating method, chromatography, antidepressants